+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North American Dry Powdered Inhaler Market 2019-2025

  • ID: 4988012
  • Report
  • January 2020
  • Region: North America, United States
  • Orion Market Research Private Limited

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • AstraZeneca PLC
  • Koninklijke Philips N.V.
  • Novartis AG
  • Pulmatrix Inc.
  • MORE
North American Dry Powdered Inhaler Market Size, Share & Trends Analysis Report by Type (Preventive Inhaler, Reliever Inhaler, and Long Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025.

North American dry powdered inhaler market was $7.2 billion in 2018 and is anticipated to grow at a substantial rate of 1.8% during the forecast period. The major factors that are contributing significantly in the market growth include rising air pollution, growing geriatric population, and high healthcare expenditure. The US and Canada are the major economies of North America. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of dry powdered inhaler market in North America region. The increasing demand for inhaler due to increasing COPD and asthma patients in the US have endorsed the approval of cohesive reimbursement policies in the US, is further fueling the growth of the market. The US is the major market due to greater healthcare expenditure and higher prevalence rate of respiratory diseases.

The North American dry powdered inhaler market is segmented on the basis of type, application, and end-user. Based on the type, preventive, reliever, and long acting bronchodilators inhaler are analyzed. Preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. The preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in market include Budesonide and Fluticasone. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing dry powdered inhaler to cater to a wide range of customers within the region and across the globe. The major players of the North American inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp. (Propeller Health), Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Research Methodology

The market study of the North American dry powdered inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for dry powdered inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. North American Dry Powdered Inhaler Market Research and Analysis by Type

2. North American Dry Powdered Inhaler Market Research and Analysis by Application

3. North American Dry Powdered Inhaler Market Research and Analysis by End-User

The Report Covers
  • Comprehensive research methodology of the North American dry powdered inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the North American dry powdered inhaler market.
  • Insights about market determinants which are stimulating the North American dry powdered inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3M Co.
  • Adherium Ltd.
  • AstraZeneca PLC
  • Koninklijke Philips N.V.
  • Novartis AG
  • Pulmatrix Inc.
  • MORE
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments

4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities

5. Market Segmentation
5.1. North American Dry Powdered Inhaler Market by Type
5.1.1. Preventive Dry Powdered Inhaler
5.1.2. Reliever Dry Powdered Inhaler
5.1.3. Long Acting Bronchodilators Dry Powdered Inhaler
5.2. North American Dry Powdered Inhaler Market by Application
5.2.1. Asthma
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.3. North American Dry Powdered Inhaler Market by End-User
5.3.1. Homecare
5.3.2. Hospitals and Clinics

6. Regional Analysis
6.1. US
6.2. Canada

7. Company Profiles
7.1. 3M Co.
7.2. Acorda Therapeutics, Inc.
7.3. Adamis Pharmaceuticals Corp.
7.4. Adherium Ltd.
7.5. Aradigm Corp.
7.6. AstraZeneca PLC
7.7. Boehringer Ingelheim International GmbH
7.8. Drive Devilbiss Healthcare LLC
7.9. GlaxoSmithKline PLC
7.10. Koninklijke Philips N.V.
7.11. Manta Devices LLC
7.12. Novartis AG
7.13. Omron Healthcare Inc.
7.14. ResMed Corp.
7.15. Pulmatrix Inc.
7.16. Savara, Inc.
7.17. Sunovion Pharmaceuticals
7.18. Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown
  • 3M Co.
  • Acorda Therapeutics, Inc.
  • Adamis Pharmaceuticals Corp.
  • Adherium Ltd.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Drive Devilbiss Healthcare LLC
  • GlaxoSmithKline PLC
  • Koninklijke Philips N.V.
  • Manta Devices LLC
  • Novartis AG
  • Omron Healthcare Inc.
  • ResMed Corp.
  • Pulmatrix Inc.
  • Savara, Inc.
  • Sunovion Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll